Gene therapy for mesothelioma

Current Treatment Options in Oncology

Volumn 12, Issue 2, 2011, Pages 173-180

  Vachani, Anil ^a   Moon, Edmund ^a   Albelda, Steven M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; ANTISENSE OLIGONUCLEOTIDE; BETA INTERFERON; GANCICLOVIR; INTERLEUKIN 2; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR; RETROVIRUS VECTOR; THYMIDINE KINASE; UNCLASSIFIED DRUG; VACCINIA VECTOR; VIRUS VECTOR;

ADOPTIVE TRANSFER; ANTISENSE THERAPY; ARTICLE; BYSTANDER EFFECT; CLINICAL TRIAL (TOPIC); CYTOKINE GENE THERAPY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; IN VITRO GENE TRANSFER; INNATE IMMUNITY; MALIGNANT PLEURA MESOTHELIOMA; MESOTHELIOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; OVARY CARCINOMA; PLEURA CANCER; PLEURA EFFUSION; PLEURA MESOTHELIOMA; SUICIDE GENE THERAPY; SURVIVAL RATE; T LYMPHOCYTE; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

CLINICAL TRIALS AS TOPIC; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MESOTHELIOMA; PLEURAL NEOPLASMS; T-LYMPHOCYTES;

EID: 79958072205     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-011-0153-5     Document Type: Article

References (30)

1. AM Maguire F Simonelli EA Pierce EN Pugh Jr F Mingozzi J Bennicelli S Banfi KA Marshall F Testa EM Surace S Rossi A Lyubarsky VR Arruda B Konkle E Stone J Sun J Jacobs L Dell'Osso R Hertle JX Ma TM Redmond X Zhu B Hauck O Zelenaia KS Shindler MG Maguire JF Wright NJ Volpe JW McDonnell A Auricchio KA High J Bennett 2008 Safety and efficacy of gene transfer for Leber's congenital amaurosis N Engl J Med 358 2240 2248 18441370 10.1056/NEJMoa0802315 1:CAS:528:DC%2BD1cXmt1Gisro%3D (Pubitemid 351724453)
2. A Fischer M Cavazzana-Calvo 2008 Gene therapy of inherited diseases Lancet 371 2044 2047 18555917 10.1016/S0140-6736(08)60874-0 (Pubitemid 351799862)
3. LS Young PF Searle D Onion V Mautner 2006 Viral gene therapy strategies: from basic science to clinical application J Pathol 208 299 318 16362990 10.1002/path.1896 1:CAS:528:DC%2BD28XhsFKjsrg%3D (Pubitemid 43126122)
4. H Bachtarzi M Stevenson K Fisher 2008 Cancer gene therapy with targeted adenoviruses Expert Opin Drug Deliv 5 1231 1240 18976133 10.1517/ 17425240802507636 1:CAS:528:DC%2BD1cXhtlaisrbE
5. JT Douglas 2007 Adenoviral vectors for gene therapy Mol Biotechnol 36 71 80 17827541 10.1007/s12033-007-0021-5 1:CAS:528:DC%2BD2sXms1OntbY%3D (Pubitemid 350133603)
6. K Breckpot PU Emeagi K Thielemans 2008 Lentiviral vectors for anti-tumor immunotherapy Curr Gene Ther 8 438 448 19075627 10.2174/156652308786848058 1:CAS:528:DC%2BD1MXhtVSkt74%3D
7. A Schambach C Baum 2008 Clinical application of lentiviral vectors-concepts and practice Curr Gene Ther 8 474 482 19075630 10.2174/156652308786848049 1:CAS:528:DC%2BD1MXhtVSkt70%3D
8. S Daya KI Berns 2008 Gene therapy using adeno-associated virus vectors Clin Microbiol Rev 21 583 593 18854481 10.1128/CMR.00008-08 1:CAS:528: DC%2BD1cXhtlClurfN
9. BR Schultz JS Chamberlain 2008 Recombinant adeno-associated virus transduction and integration Mol Ther 16 1189 1199 18500252 10.1038/mt.2008.103 1:CAS:528:DC%2BD1cXns1eiurk%3D (Pubitemid 351866049)
10. DA Garber LA O'Mara J Zhao S Gangadhara I An MB Feinberg 2009 Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies PLoS One 4 e5445 19421328 10.1371/journal.pone. 0005445
11. DH Kirn SH Thorne 2009 Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer Nat Rev Cancer 9 64 71 19104515 10.1038/nrc2545 1:CAS:528:DC%2BD1MXpt1eh
12. S Chesnoy L Huang 2000 Structure and function of lipid-DNA complexes for gene delivery Annu Rev Biophys Biomol Struct 29 27 47 10940242 10.1146/annurev.biophys.29.1.27 1:CAS:528:DC%2BD3cXlsFOntbo%3D (Pubitemid 30599587)
13. T Niidome L Huang 2002 Gene therapy progress and prospects: nonviral vectors Gene Ther 9 1647 1652 12457277 10.1038/sj.gt.3301923 1:CAS:528:DC%2BD38XptFCisbo%3D (Pubitemid 36104607)
14. P Tiberghien 1994 Use of suicide genes in gene therapy J Leukoc Biol 56 203 209 8071596 1:CAS:528:DyaK2cXmt1Srsbo%3D (Pubitemid 24270503)
15. T Matthews R Boehme 1988 Antiviral activity and mechanism of action of ganciclovir Rev Infect Dis 10 Suppl 3 S490 4 2847285 10.1093/clinids/10. Supplement-3.S490 1:CAS:528:DyaL1cXls1aksLg%3D
16. DH Sterman J Treat LA Litzky KM Amin L Coonrod K Molnar-Kimber A Recio L Knox JM Wilson SM Albelda LR Kaiser 1998 Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma Hum Gene Ther 9 1083 1092 9607419 10.1089/hum.1998.9.7-1083 1:CAS:528: DyaK1cXivFKrt78%3D (Pubitemid 28236516)
17. DH Sterman A Recio A Vachani J Sun L Cheung P DeLong KM Amin LA Litzky JM Wilson LR Kaiser SM Albelda 2005 Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy Clin Cancer Res 11 7444 7453 16243818 10.1158/1078-0432.CCR-05-0405 1:CAS:528:DC%2BD2MXhtFartbvJ (Pubitemid 41507705)
18. LH Harrison Jr PO Schwarzenberger PS Byrne AJ Marrogi JK Kolls KE McCarthy 2000 Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma Ann Thorac Surg 70 407 411 10969653 10.1016/S0003-4975(00)01557-5 (Pubitemid 30650964)
19. S Mukherjee T Haenel R Himbeck B Scott I Ramshaw RA Lake G Harnett P Phillips S Morey D Smith JA Davidson AW Musk B Robinson 2000 Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation Cancer Gene Ther 7 663 670 10830713 10.1038/sj.cgt.7700133 1:CAS:528:DC%2BD3cXjsF2gsb8%3D (Pubitemid 30314050)
20. Pitako J, Squiban P, Acres B. A randomized phase II single center study of gene transfer-based non-specific immunotherapy of malignant mesothelioma (MM) by intratumoral injections of an interleukin-2 producing vero cells [abstract]. Proceedings of the American Society of Clinical Oncology 2003;22.
21. DH Sterman CT Gillespie RG Carroll CM Coughlin EM Lord J Sun A Haas A Recio LR Kaiser G Coukos CH June SM Albelda RH Vonderheide 2006 Interferon beta adenoviral gene therapy in a patient with ovarian cancer Nat Clin Pract Oncol 3 633 639 17080181 10.1038/ncponc0658 (Pubitemid 44669718)
22. DH Sterman A Recio RG Carroll CT Gillespie A Haas A Vachani V Kapoor J Sun R Hodinka JL Brown MJ Corbley M Parr M Ho I Pastan M Machuzak W Benedict XQ Zhang EM Lord LA Litzky DF Heitjan CH June LR Kaiser RH Vonderheide SM Albelda M Kanther 2007 A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses Clin Cancer Res 13 4456 4466 17671130 10.1158/1078-0432.CCR-07-0403 1:CAS:528:DC%2BD2sXotlGqtL8%3D (Pubitemid 47219714)
23. DH Sterman A Recio AR Haas A Vachani SI Katz CT Gillespie G Cheng J Sun E Moon L Pereira X Wang DF Heitjan L Litzky CH June RH Vonderheide RG Carroll SM Albelda 2010 A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions Mol Ther 18 852 860 20068553 10.1038/mt.2009.309 1:CAS:528: DC%2BC3cXksFGkug%3D%3D First study to demonstrate the feasibility, safety, and preliminary evidence of efficacy in patients with mesothelioma using two doses of intrapleural adenoviral mediated interferon-beta gene therapy
24. ES Lambright SD Force ME Lanuti DS Wasfi KM Amin SM Albelda LR Kaiser 2000 Efficacy of repeated adenoviral suicide gene therapy in a localized murine tumor model Ann Thorac Surg 70 1865 70 11156085 10.1016/S0003-4975(00)01815-4 1:STN:280:DC%2BD3M%2FpvFeruw%3D%3D (Pubitemid 32015275)
25. MH Kershaw MW Teng MJ Smyth PK Darcy 2005 Supernatural T cells: genetic modification of T cells for cancer therapy Nat Rev Immunol 5 928 940 16322746 10.1038/nri1729 1:CAS:528:DC%2BD2MXht1KntrzL (Pubitemid 41746762)
26. CH June 2007 Adoptive T cell therapy for cancer in the clinic J Clin Invest 117 1466 1476 17549249 10.1172/JCI32446 1:CAS:528:DC%2BD2sXmsVWktb8%3D (Pubitemid 46871329)
27. S Bobisse M Rondina A Merlo V Tisato S Mandruzzato M Amendola L Naldini RA Willemsen R Debets P Zanovello A Rosato 2009 Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors Cancer Res 69 9385 9394 19996290 10.1158/0008-5472.CAN-09-0494 1:CAS:528:DC%2BD1MXhsFGrtbnL
28. E Yvon M Del Vecchio B Savoldo V Hoyos A Dutour A Anichini G Dotti MK Brenner 2009 Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells Clin Cancer Res 15 5852 5860 19737958 10.1158/1078-0432. CCR-08-3163 1:CAS:528:DC%2BD1MXhtFars73F
29. C Carpenito MC Milone R Hassan JC Simonet M Lakhal MM Suhoski A Varela-Rohena KM Haines DF Heitjan SM Albelda RG Carroll JL Riley I Pastan CH June 2009 Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains Proc Natl Acad Sci U S A 106 3360 3365 19211796 10.1073/pnas.0813101106 1:CAS:528: DC%2BD1MXivF2jsbw%3D Study showing that lentiviral vectors can be used to generate mesothelin-retargeted T-cells that can eradicate in mesothelioma xenografts in a mouse model. These findings have important implications for adoptive immunotherapy of cancer, especially in the context of poorly immunogenic tumors
30. Y Zhao E Moon C Carpenito CM Paulos X Liu AL Brennan A Chew RG Carroll J Scholler BL Levine SM Albelda CH June 2010 Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor Cancer Res 70 9053 9061 20926399 10.1158/0008-5472. CAN-10-2880 1:CAS:528:DC%2BC3cXhsVWmsL3F This is the first report using matched patient tumor and lymphocytes showing that autologous T cells from cancer patients can be gene modified using RNA electroporation to provide an effective therapy for a disseminated tumor in a robust preclinical model